125 related articles for article (PubMed ID: 30497813)
1. Genetic assessment of recurrent pancreatic high-risk lesions in the remnant pancreas: Metachronous multifocal lesion or local recurrence?
Gotoh Y; Ohtsuka T; Nakamura S; Shindo K; Ohuchida K; Miyasaka Y; Mori Y; Mochidome N; Oda Y; Nakamura M
Surgery; 2019 Apr; 165(4):767-774. PubMed ID: 30497813
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
[TBL] [Abstract][Full Text] [Related]
3. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.
Hashimoto D; Arima K; Nakagawa S; Negoro Y; Hirata T; Hirota M; Inomata M; Fukuzawa K; Ohga T; Saeki H; Oki E; Yamashita YI; Chikamoto A; Baba H; Maehara Y
J Gastroenterol; 2019 May; 54(5):437-448. PubMed ID: 30515563
[TBL] [Abstract][Full Text] [Related]
5. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4.
Hosoda W; Chianchiano P; Griffin JF; Pittman ME; Brosens LA; Noë M; Yu J; Shindo K; Suenaga M; Rezaee N; Yonescu R; Ning Y; Albores-Saavedra J; Yoshizawa N; Harada K; Yoshizawa A; Hanada K; Yonehara S; Shimizu M; Uehara T; Samra JS; Gill AJ; Wolfgang CL; Goggins MG; Hruban RH; Wood LD
J Pathol; 2017 May; 242(1):16-23. PubMed ID: 28188630
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis.
Fujita Y; Matsuda S; Sasaki Y; Masugi Y; Kitago M; Yagi H; Abe Y; Shinoda M; Tokino T; Sakamoto M; Kitagawa Y
Cancer Sci; 2020 Feb; 111(2):739-748. PubMed ID: 31799787
[TBL] [Abstract][Full Text] [Related]
7. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
[TBL] [Abstract][Full Text] [Related]
8. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.
Masugi Y; Takamatsu M; Tanaka M; Hara K; Inoue Y; Hamada T; Suzuki T; Arita J; Hirose Y; Kawaguchi Y; Nakai Y; Oba A; Sasahira N; Shimane G; Takeda T; Tateishi K; Uemura S; Fujishiro M; Hasegawa K; Kitago M; Takahashi Y; Ushiku T; Takeuchi K; Sakamoto M;
J Pathol Clin Res; 2023 Sep; 9(5):339-353. PubMed ID: 37291757
[TBL] [Abstract][Full Text] [Related]
9. Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy.
Ishida J; Toyama H; Matsumoto I; Asari S; Goto T; Terai S; Nanno Y; Yamashita A; Mizumoto T; Ueda Y; Kido M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2016; 16(4):615-20. PubMed ID: 27237099
[TBL] [Abstract][Full Text] [Related]
10. Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas.
Ohtsuka T; Kono H; Tanabe R; Nagayoshi Y; Mori Y; Sadakari Y; Takahata S; Oda Y; Aishima S; Igarashi H; Ito T; Ishigami K; Nakamura M; Mizumoto K; Tanaka M
Am J Surg; 2012 Jul; 204(1):44-8. PubMed ID: 21996346
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
[No Abstract] [Full Text] [Related]
12. Clinical Effect of Driver Mutations of
Gu Y; Ji Y; Jiang H; Qiu G
Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
[No Abstract] [Full Text] [Related]
13. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
14. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary.
Luchini C; Pea A; Yu J; He J; Salvia R; Riva G; Weiss MJ; Bassi C; Cameron JL; Hruban RH; Goggins M; Wolfgang CL; Scarpa A; Wood LD; Lawlor RT
Mod Pathol; 2019 May; 32(5):659-665. PubMed ID: 30467323
[TBL] [Abstract][Full Text] [Related]
16. Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
Wright GP; Chesla DW; Chung MH
Am J Surg; 2016 Mar; 211(3):506-11. PubMed ID: 26754455
[TBL] [Abstract][Full Text] [Related]
17. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Loukopoulos P; Kanetaka K; Takamura M; Shibata T; Sakamoto M; Hirohashi S
Pancreas; 2004 Oct; 29(3):193-203. PubMed ID: 15367885
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characteristics of Pancreatic Ductal Adenocarcinomas with High-Grade Pancreatic Intraepithelial Neoplasia (PanIN) Are Different from Those without High-Grade PanIN.
Miyazaki T; Ohishi Y; Miyasaka Y; Oda Y; Aishima S; Ozono K; Abe A; Nagai E; Nakamura M; Oda Y
Pathobiology; 2017; 84(4):192-201. PubMed ID: 28291966
[TBL] [Abstract][Full Text] [Related]
19. Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data.
Baek B; Lee H
Sci Rep; 2020 Nov; 10(1):18951. PubMed ID: 33144687
[TBL] [Abstract][Full Text] [Related]
20. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
